We are live on ! Find out more
INM icon

InMed Pharmaceuticals
INM

6 hedge funds and large institutions have $2.99M invested in InMed Pharmaceuticals in 2021 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

214% more capital inflows, than outflows

Capital inflows: $2.1M | Capital outflows: $667K

5.94% more ownership

Funds ownership: 5.8% → 11.74% (+5.9%)

0% more repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 1

25% less funds holding

Funds holding: 8 → 6 (-2)

50% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 4

Holders
6
Holders Change
-2
Holders Change %
-25%
% of All Funds
0.1%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
1
Reduced
1
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Armistice Capital
Armistice Capital
New York
+$2.03M
2
Penserra Capital Management
Penserra Capital Management
California
+$61.9K
3
UBS Group
UBS Group
Switzerland
+$7.74K

Top Sellers

Rank Fund Capital Flow
1
Hudson Bay Capital Management
Hudson Bay Capital Management
Connecticut
-$531K
2
Bank of America
Bank of America
North Carolina
-$53K
3
Morgan Stanley
Morgan Stanley
New York
-$38.7K
4
JP Morgan Chase
JP Morgan Chase
New York
-$36K
5
Citadel Advisors
Citadel Advisors
Florida
-$7.74K

INM Hedge Fund Activity: Q2 2021 in Review

6 of the 5,769 institutional investors tracked by Wall St. Rank reported a position in InMed Pharmaceuticals (INM) for Q2 2021, worth a combined $2.99M — up 93% from $1.55M a quarter earlier.

Sellers outnumbered buyers: 4 funds closed out of INM and 2 opened new positions — a net loss of 2 holders — while 1 trimmed existing stakes and 1 added.

The largest buyer was Armistice Capital, adding an estimated $2.03M. The largest seller was Hudson Bay Capital Management, exiting entirely with an estimated $531K sold.

  • 6 institutional investors held InMed Pharmaceuticals (INM) as of Q2 2021, down from 8 in Q1 2021.
  • Funds reported $2.99M of InMed Pharmaceuticals stock for Q2 2021, up 93% quarter-over-quarter.
  • 2 funds opened new InMed Pharmaceuticals positions in Q2 2021 and 4 closed out, a net change of -2 holders.
  • The largest InMed Pharmaceuticals buyer in Q2 2021 was Armistice Capital, an estimated $2.03M added.
  • The largest InMed Pharmaceuticals seller in Q2 2021 was Hudson Bay Capital Management, an estimated $531K sold.

Based on aggregated 13F filings for Q2 2021.